This live Symposium is approved for 8.75 AMA PRA Category 1 Credit(s)TM and 8.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM)

Maintenance of Certification (MOC) program, 8.5 CNE contact hours, and 8.5 CPE contact hours by the Purdue University College of Pharmacy.

17th AnnualIndy Hematology Review

Organized by: Indy Hematology Education, Inc.

Presented by:

Saturday, March 21, 2020The Westin Indianapolis 241 W. Washington St.Indianapolis, IN 46204

A full day of presentations by today’s leaders in Hematology and Hematologic Malignancies

Achieving tomorrow’s outcomes through education today.

Register online: www.indyhematologyreview.com

Participating in the Symposium will affect competence, performance and patient outcomes in a variety of ways:1. �Attendees�will�be�able�to�implement�the�most�clinically�effective�management�strategies�for�the�

various�types�and�stages�of�lymphoma,�leukemia,�and�multiple�myeloma�to�improve�patient�care.2. �Attendees�will�know�and�understand�how�to�apply�updated�research�in�the�diagnosis�and�

treatment�of�Waldenström’s�Macroglobulinemia.3. �Attendees�will�know�the�new�advancements�in�immune�check�point�inhibitors�within�

hematologic�malignancies�and�use�case�reports�and�summary�information�to�update�their�knowledge�in�hematologic�malignancies.��

4. �Attendees�will�have�knowledge�of�new�treatment�regimens�for�Hematopoietic�Stem�Cell�transplant�and�know�when�to�apply�relevant�treatment�and�when�to�avoid.

5. Attendees�will�know�up�to�date�research�information�on�benign�hematology.6. �Attendees�will�be�updated�on�new�management�strategies�in�follicular�lymphoma,�with�updated�

first�line,�second�line,�and�maintenance�treatment�options.

This�Symposium�is�designed�to�provide�a�valuable�educational�experience�to�keep�you�informed�and�up�to�date�about�the�most�important�topics�in�hematology.�Stay�current�with�a�concise�summary�of�the�critical�data�presented�at�the�American�Society�of�Hematology�(ASH)�annual�meeting.��Network�with�thought�leaders�in�the�field�and�more�than�400�hematology�professionals�from�across�the�country.

The�Indy�Hematology�Review�brings�together�over�400�hematologists,�oncologists,�radiologists,�physician�assistants,�oncology�RN’s,�nurse�practitioners,�pharmacists,�medical�students,�and�other�allied�health�professionals�to�examine�significant�scientific�updates�in�clinical�hematologic�research,�learn�how�these�updates�directly�affect�the�study�and�practice�of�hematology,�and�discover�how�new�research�can�be�translated�into�new�patient�care�strategies.

Visit the Exhibit HallVisit�the�exhibit�hall�to�experience�the�latest�technology,�services,�devices�and�research�in�hematology.�The�exhibit�hall�offers�an�opportunity�to�learn�about�a�wide�range�of�products�and�services�offered�by�pharmaceutical�companies,�medical�suppliers,�biotechnology�companies,�healthcare�systems,�and�research-based�companies.�Stop�in�for�a�beverage�and�snack�at�the�“Physicians’�Lounge”�as�you�visit�exhibitors.

Ruemu Birhiray, MD (Chair)CEO,�Indy�Hematology�Education,�Inc.Partner�and�Vice�President,Hematology�Oncology�of�Indiana,�PC

Michael C. Wiemann, MD, FACP (Co-Chair)President,�Providence�HospitalExecutive�Vice�President�West�Region,�St.�John�Providence�Health�System

Donna Birhiray, OTR, MBAIndy�Hematology�Education,�Inc.Treasurer

Thalia HammondIndy�Hematology�Education,�Inc. Board�of�Director

Jennifer Wheeler-Terry, JDWabash�College Board�of�Director

Debbie LocklearMeeting�Services�Unlimited,�Inc.President

Tina Machina, CMPMeeting�Services�Unlimited,�Inc.Director�of�Conventions

INDY HEMATOLOGY EDUCATION, INC.Achieving tomorrow’s outcomes through education today.Indy�Hematology�Education,�Inc.�is�a�501(c),�non-profit�corporation,�incorporated�on�February�15,�2010,�in�the�State�of�Indiana,�with�the�following�purposes:

� (a)��Raise�awareness�and�provide�education�regarding�hematology�and�oncology�diseases�and�disorders

� (b)��To�encourage�youth�to�pursue�careers�in�hematology�and�oncology�and�

� (c)��To�connect�individuals�suffering�from�or�affected�by�hematology�and�oncology�diseases�and�disorders�to�organizations,�programs,�and�service�providers.

PLANNING COMMITTEESUPPORTERS & SPONSORSHIPS

The 2020 Indy Hematology Review is supported by: Agios

Alexion PharmaceuticalsAmgen

AstraZenecaBeiGene Ltd

Bristol-Myers SquibbBTG International, Inc

Clovis OncologyCoherus BioSciences

ImmunomedicsIncyte CorporationJanssen Oncology

Jazz PharmaceuticalsNovo Nordisk, Inc

Pfizer, Inc.Rigel Pharmaceuticals

Seattle GeneticsSanofi Genzyme

Stemline Therapeutics

BOARD OF DIRECTORSRuemu�E.�Birhiray,�MD,�President�and�CEO�

Michael�C.�Wiemann,�MD,�FACP,�Vice-President

Donna�M.�Birhiray,�OT,�MBA,�Treasurer

Jennifer�Terry,�JD,�Secretary

Thalia�Hammond,�Director

Indiana Community Cancer Care Foundation, IncAmerican Oncology Network

Register online: www.indyhematologyreview.com

7:00 AM – 2:30 PM – Registration

7:00 AM – 4:45 PM – Exhibit displays

7:30 AM – Breakfast Product Theaters

8:30 AM – State of the Art: 2020 Emerging Therapies in Hematologic MalignanciesRuemu�E.�Birhiray,�MD�–�ChairCEO,�Indy�Hematology�Education,�Inc.Associate�Professor�of�Clinical�Medicine,�Marian�University�of�Osteopathic�MedicinePartner�and�Vice�President,�Hematology�Oncology�of�Indiana,�PC�(Indianapolis,�IN)

9:00 AM – Emerging Treatment Paradigms in Multiple Myeloma: Targeting the Neighborhood and Beyond Kenneth�Anderson,�MDKraft�Family�Professor�of�Medicine,�Harvard�Medical�SchoolProgram�Director�of�the�Lebow�Institute�for�Myeloma�Therapeutics�and�Jerome�Lipper�Multiple�Myeloma�Center,�Dana-Farber�Cancer�Institute�(Boston,�MA)

9:30 AM – Waldenström’s Macroglobulinemia: Choosing Wisely in Prognostication and Treatment in 2020Steven�Treon,�MD,�MA,�PhD,�FACP,�FRCPAssociate�Professor�of�Medicine,�Harvard�Medical�SchoolSenior�Attending�Physician�for�Medical�Oncology�at�DFCI�and�Brigham�&�Women’s�HospitalDirector�of�the�Bing�Center�for�Waldenström’s�Macroglobulinemia�Dana-Farber�Cancer�Institute�(Boston,�MA)

10:00 AM – Chronic Lymphocytic Leukemia: Who, When and How to Treat in 2020Steven�Coutre,�MDProfessor�of�Medicine�in�Hematology,�Stanford�University�Medical�Center�(Palo�Alto,�CA)

10:30 AM – Break with Q & A

10:45 AM – Who, When and How to Treat: The Paradox of Watching, Treatment and Retreatment in Indolent Lymphomas in 2020Bruce�Cheson,�MD,�FACP,�FAAS,�FASCOProfessor�of�Medicine,�Head�of�Hematology�and�Cellular�TherapyDeputy�Chief,�Hematology-Oncology,�and�Fellowship�Program�Director�at�Medstar�Georgetown�University�Hospital�Lombardi�Comprehensive�Cancer�Center�(Washington,�DC)

11:15 AM – Current Therapy in Aggressive B and T Cell Lymphomas: An UpdateJohn�Leonard,�MDAttending�Physician,�New�York-Presbyterian�HospitalRichard�T.�Silver�Distinguished�Professor�of�Hematology�and�Medical�OncologyAssociate�Dean�of�Clinical�Research�and�Associate�Director�of�the�Cancer�Center�atWeill�Cornell�Medical�College�(New�York,�NY)

11:45 AM – Novel Therapy of Acute Lymphoblastic Leukemia: DRIVERS, CARS and Targeted TherapyHagop�Kantarjian,�MDSamsung�Distinguished�University�Chair�in�Cancer�Medicine,�Associate�Vice�President�for�Global�Academic�Programs,Professor�and�Department�Chair,�Department�of�Leukemia,�Division�of�Cancer�MedicineThe�University�of�Texas�MD�Anderson�Cancer�Center�(Houston,�TX)

12:15 PM – Benign Hematology: Current Treatment of Cytopenias and Coagulopathies Craig�Kessler,�MDProfessor�of�Medicine�and�PathologyDirector�of�Clinical�Coagulation�Laboratory�in�Department�of�Laboratory�MedicineLombardi�Comprehensive�Cancer�CenterMedstar�Georgetown�University�Medical�Center�(Washington,�DC)

12:45 PM – Q & A

1:00 PM – Lunch Product Theaters

2:00 PM – T. HOWARD LEE KEYNOTE LECTURE: State of the Art: Current and Emerging Treatment of Hodgkin’s Lymphoma Julie�Vose,�MD,�MBAThe�Neumann�M.�and�Mildred�E.�Harris�Professor�and�Chief�in�the�Division�of�Oncology/Hematology�at�UNMC.Fred�&�Pamela�Buffett�Cancer�Center�and�Cancer�Center�at�Village�Pointe�Health�Center�(Omaha,�NE)

3:00 PM – Challenging Cases PresentationMichael�C.�Wiemann,�MD,�FACP�–�Co-ChairPresident�of�Providence�HospitalExecutive�Vice�President�West�Region,�St.�John�Providence�Health�System�(Warren,�MI)

3:25 PM – Chronic Myeloid Leukemia: Therapeutic Goals and Managing ResistanceRichard�Larson,�MDProfessor�of�Medicine�in�Hematology/Oncology,�Director�of�Hematologic�Malignancies�Clinical�Research�ProgramThe�University�of�Chicago�Comprehensive�Cancer�Center�(Chicago,�IL)

3:55 PM – A Global Perspective of Current Treatment Strategies of Myeloproliferative NeoplasmsAlessandro�Vannucchi,�MDAssociate�Professor�of�Hematology,�University�of�Florence�(Florence,�Italy)

4:25 PM – Break with Q & A

4:40 PM – Bad Blood: Treatment of Complimentinopathies and Aplastic AnemiaRobert�Brodsky,�MDDirector�of�Division�of�HematologyJohns�Hopkins�Family�Professor�of�Medicine�and�OncologyJohns�Hopkins�University�School�of�Medicine�(Baltimore,�MD)

SYMPOSIUM AGENDA

Register online: www.indyhematologyreview.com

8:30 AM – State of the Art: 2020 Emerging Therapies in Hematologic MalignanciesRuemu�E.�Birhiray,�MD�–�Chair

9:00 AM – Indolent Lymphomas and Hodgkin’s LymphomaBruce�Cheson,�MD,�FACP,�FAAS,�FASCO

9:30 AM – Benign Hematology and CoagulopathyCraig�Kessler,�MD

10:00 AM – Break with Q & A

10:10 AM – Aggressive LymphomasJulie�Vose,�MD,�MBA

10:40 AM – Chronic Leukemias Steven�Coutre,�MD

11:10 AM – Break with Q & A

11:20 AM – Myeloproliferative Neoplasms: Diagnosis, Prognostication and Treatment OptionsAlessandro�Vannucchi,�MD

11:45 AM – Management of Long-Term Survivors of Hematologic MalignanciesKristi�Orbaugh,�RN,�MSN�RNP,�AOCNAdult�Nurse�PractitionerCommunity�Hospital�Oncology�Physicians�(Indianapolis,�IN)

12:10 PM – Managing Drug Interaction with Oral Oncolytics in the Management of Hematologic MalignanciesDavid�Reeves,�PharmD,�BCOPAssociate�Professor�of�Pharmacy�Practice,�College�of�Pharmacy�and�Health�Sciences,�Butler�University�Clinical�Pharmacy�Specialist�in�Hematology/Oncology,�Franciscan�Physician�Network�Oncology/Hematology�Specialist�(Indianapolis,�IN)

12:35 PM – Multiple Myeloma and Waldenström’sMorie�Gertz,�MD

12:55 PM – Break with Q & A

1:00 PM – Lunch: Product Theaters

2:00 PM – Adjourn and join General Session for T. Howard Lee Lecture

NURSING AND ALLIED PROVIDERS SYMPOSIUM AGENDA

Disclosure information, biographies, and slides (where authorized by the presenter) will be available at indyhematologyreview.com

5:10 PM – Acute Myeloid Leukemia: Prognostication, Targeting and Sequencing TherapiesMartin�Tallman,�MDChief�of�Leukemia�Service�and�Professor�of�MedicineMemorial�Sloan-Kettering�Cancer�CenterWeill�Cornell�Medical�College�(New�York,�NY)

5:40 PM – Myelodysplastic Syndrome: What is New in 2020?Richard�Stone,�MDChief�of�Staff�and�Director�of�Translational�Research,�Adult�Leukemia�ProgramProfessor�of�Medicine,�Harvard�Medical�School�Dana-Farber�Cancer�Institute�(Boston,�MA)

6:10 PM – How I Treat: The Practice of Hematopoietic Stem Cell Transplantation in 2020Richard�Childs,�MD,�RADM,�USPHSClinical�Director,�National�Heart,�Lung,�and�Blood�Institute�(NHLBI)National�Institutes�of�Health�(Bethesda,�MD)

6:40 PM – Break

7:00 PM – Town Hall Reception

7:00 PM – 8:30 PM – Hematologic Malignancies Town HallRuemu�E.�Birhiray,�MD.�ChairMorie�Gertz,�MD,�MACPRoland�Seidler�Jr.�Professor,�Art�of�Medicine,�Chair�Emeritus,�Department�of�Internal�Medicine,�Mayo�Clinic�(Rochester,�MN)Harry�Erba,�MD,�PhD

Professor,�Medicine�Director,�Leukemia�Program,�Duke�University�(Durham,�NC)C.�Ola�Landgren,�MD,�PhDChief�of�Myeloma�Service,�Division�of�Hematologic�Oncology,Memorial�Sloan�Kettering�Cancer�CenterProfessor�of�Medicine,�Weill�Cornell�Medical�College�(New�York,�NY)Steven�Coutre,�MDJohn�Leonard,�MDSteven�Coutre,�MDC.�Ola�Landgren,�MD,�PhDChief�of�Myeloma�Service,�Division�of�Hematologic�Oncology,�Memorial�Sloan�Kettering�Cancer�CenterProfessor�of�Medicine,�Weill�Cornell�Medical�College�(New�York,�NY)

MODERATORS: Donna M. Birhiray, OTR, MBA and Thalia Hammond

Register online: www.indyhematologyreview.com

To�register�online,�go�to�indyhematologyreview.comand�click�on�“Register.”

Early Bird Registration: ends February 24, 2020Early�Bird�Physicians� � � � � � � $225.00Early�Bird�Allied�Health�&�Nurses�� � � � � $150.00Early�Bird�Nurse�Practitioners�&�Pharmacists� � � � $175.00Industry�&�Exhibitors� � � � � � � $375.00Student/Fellow�Scholarship*�(Limited�Number)� � � � $50.00Nurse�Scholarship*�(Limited�Number)� � � � � $50.00

Standard Registration: after February 24, 2020Physicians� � � � � � � � $275.00Allied�Health�&�Nurses� � � � � � � $200.00Nurse�Practitioners�&�Pharmacists� � � � � $225.00Industry�&�Exhibitors� � � � � � � $375.00Student/Fellow�Scholarship*�(Limited�Number)� � � � $50.00Nurse�Scholarship*�(Limited�Number)� � � � � $50.00 *A limited number of scholarships are available on a first-come, first-serve basis, based on approval.

NOTE:�When�registering�healthcare�providers�from�your�office,�fill�in�the�person’s�full�name�and�email�address�so�the post-event�survey�and�certificate�for�continuing�education�credits�are�emailed�directly�to�each�person.

REGISTRATION

REFUND POLICYRequest�a�registration�cancellation�refund�on�or�before�March�6,�2020,�to�receive�a�Full�Refund.�After�March�6,�2020,�there�is�NO�REFUND.

HOTEL RESERVATIONSMake�reservations�online to reserve a room.�You�may�call�The�Westin�Indianapolis�toll�free�at�1-800-937-8461.Mention�“Indy�Hematology�Review”�for�the�discounted�group�rate�of�$160�plus�tax�(currently�17%).�The�block�of�discounted�rooms�will�close�on�Friday,�March�6,�2020.

PARKINGParking�is�available�at�The�Westin�Indianapolis.�24-hour�parking�rates�are�currently:�$40.00�on-site�parking;�$45.00�valet�(rates�are�subject�to�change�without�notice).

Self-parking�is�also�available�at�the�Government�Center�Washington�St.�Parking�Facility,�401�West�Washington�Street.�Daily�Maximum�currently:�$25.00�(rates�are�subject�to�change�without�notice).

PHOTOGRAPHYPhotos�of�attendees�will�be�taken�throughout�the�Symposium.�These�photos�are�for�Indy�Hematology�Review�and�Indy�Hematology�Education,�Inc.�use�only�and�may�appear�on�the�IHR�website,�in�promotional�brochures,�or�other�future�promotional�material.��By�virtue�of�your�attendance,�you�agree�to�usage�of�your�photograph�in�such�media,�unless�we�are�otherwise�notified�in�writing�and�receive�a�clear�photo�of�you.

QUESTIONS? Please�contact�317-841-7171, Indyhr@conventionmanagers.com.

Register online: www.indyhematologyreview.com

CONTINUING EDUCATION INFORMATIONPHYSICIANS

In�order�to�receive�CE,�you�must�attend�the�entire�Symposium�from�8:30�am�–�6:50�pm.�Successful�completion�of�this�CME�activity�requires�participants�to�complete�a�Post-Evaluation.

Successful�completion�of�this�CME�activity,�which�includes�participation�in�the�evaluation�component,�enables�the�participant�to�earn�up�to�8.75�Medical�Knowledge�MOC�points�in�the�American�Board�of�Internal�Medicine’s�(ABIM)�Maintenance�of�Certification�(MOC)�program.�It�is�the�CME�activity�provider’s�responsibility�to�submit�participant�completion�information�to�ACCME�for�the�purpose�of�granting�ABIM�MOC�credit.�

LEARNING OBJECTIVES (ACCME, ANCC, ACPE)1.��Discuss�new�emerging�hematology�therapies�in�general�and�for�chronic�Myeloid�Leukemia,�acute�Promyelocytic,�and�Myeloproliferative�neoplasms.

2.��Evaluate�molecular�diagnosis,�targeted�therapies,�and�resistance�mechanisms�of�Waldenström’s�Macroglobulinemia�to�assist�in�disease�recognition.

3.��Discuss�the�advancement�of�immune�check�point�inhibitors�within�hematologic�malignancies�and�updated�treatment�paradigms�presented�at�the�American�Society�of�Hematology�meeting�in�Orlando,�FL�in�December�2019.

4.��Recommend�new�regimens�for�Hematopoietic�Stem�Cell�transplantation�and�identification�of�transplant�candidates.�

5.��Review�the�advancement�in�hematology�research�and�treatment�of�diseases�of�coagulopathy,�compliment�and�cytopenia.

6.��Review�current�and�emerging�treatment�regimens�in�lymphomas.7.��Review�and�update�advances�in�the�treatment�of�disorders�of�compliment�and�aplastic�anemia.

8.��Present�challenging�clinical�cases�and�discuss�management�strategies�of�hematologic�malignancies�and�disorders�with�the�application�of�current�and�emerging�medical�literature.

CME ACCREDITATION STATEMENTThis�live�activity�has�been�planned�and�implemented�in�accordance�with�the�accreditation�requirements�and�policies�of�the�Accreditation�Council�for�Continuing�Medical�Education�(ACCME)�through�the�joint�providership�of�Purdue�University�College�of�Pharmacy�and�Indy�Hematology�Education,�Inc.��Purdue�University�is�accredited�by�the�ACCME�to�provide�continuing�medical�education�for�physicians.

DESIGNATION STATEMENTPurdue�University�College�of�Pharmacy�designates�this�live�activity�for�a�maximum�of�8.75 AMA PRA Category 1 Credit(s)™. Symposium�-�8�am�-�6:30�pm.��Purdue�University�College�of�Pharmacy�designates�this�live�activity�for�a�maximum�of�1.50�AMA�PRA�Category�1�Credit�TM�(Town�Hall�Interactive�Meeting�-�7�-�8:30�pm).�Physicians�should�claim�only�the�credit�commensurate�with�the�extent�of�their�participation�in�the�activity.

DISCLOSURE STATEMENTAll�faculty,�staff,�and�reviewers�involved�in�the�planning,�review,�or�presentation�of�continuing�education�activities�provided�by�Purdue�University�College�of�Pharmacy�are�required�to�disclose�to�the�audience�any�relevant�commercial�financial�affiliations�related�to�the�content�of�the�presentation�or�enduring�material.��Full�disclosure�of�all�commercial�relationships�must�be�made�in�writing�to�the�audience�prior�to�the�activity.��All�additional�planning�committee�members,�staff,�and�reviewers�of�Indy�Hematology�Education,�Inc.�and�Purdue�University�College�of�Pharmacy�have�no�relationships�to�disclose.�

NOTE:�While�it�offers�CME�credits,�this�activity�is�not�intended�to�provide�extensive�training�or�certification�in�the�field.

NURSESIn�order�to�receive�CE,�you�must�attend�the�entire�Symposium�from�8:30�am�–�6:50�pm.�Successful�completion�of�this�CME�activity�requires�participants�to�complete�a�Post-Evaluation.

CNE ACCREDITATION STATEMENTPurdue�University�Continuing�Nursing�Education�is�accredited�as�a�provider�of�continuing�nursing�education�with�distinction�by�the�American�Nurses�Credentialing�Center’s�Commission�on�Accreditation.��

This�program�is�approved�for�8.5 contact hours.

(Symposium:��8:30�am�-�6:30�pm)This�program�is�approved�for�1.50 contact hours(Town�Hall�Interactive�Meeting:��7�-�8:30�pm).

PHARMACISTSIn�order�to�receive�CE,�you�must�attend�the�entire�Symposium�from�8:30�am�–�6:50�pm.�Successful�completion�of�this�CME�activity�requires�participants�to�complete�a�Post-Evaluation.

CPE ACCREDITATION STATEMENTPurdue�University�College�of�Pharmacy�is�accredited�by�the�Accreditation�Council�for�Pharmacy�Education�as�a�provider�of�continuing�pharmacy�education.��This�is�a�knowledge�based,�continuing�education�activity�of�Purdue�University,�an�equal�access/equal�opportunity�institution.�

Universal�Activity�Number�(UAN):�0018-9999-20-001-L01-PThis�program�is�approved�for�8.5�contact�hours�(0.85�CEU’s).Symposium:��8:30�am�-�6:30�pm.

Town�Hall�Interactive�Meeting:��7�-�8:30�pmUniversal�Activity�Number�(UAN):�0018-9999-20-002-L01-PThis�program�is�approved�for�1.5 contact hours�(0.15�CEU’s).

Presented by:

Indy Hematology Review�C/O�Meeting�Services�Unlimited135�S.�Mitthoeffer�Rd.Indianapolis,�IN�46229

17th AnnualIndy Hematology Review

Saturday, March 21, 2020The Westin Indianapolis 241 W. Washington St.Indianapolis, IN 46204

Organized by:

Achieving tomorrow’s outcomes through education today.